Muhammad Hameed Khan | Epidemiology | Editorial Board Member

Published on by Global Academic Awards

Mr. Muhammad Hameed Khan | Epidimiology | Editorial Board Member

Quaid-i-Azam University | Pakistan

Mr. Muhammad Hameed Khan is an emerging researcher in medical entomology, parasitology, and infectious disease ecology, with strong expertise in molecular diagnostics, epidemiology, and vector-borne disease surveillance. His research integrates molecular tools, biodiversity assessment, and ecological mapping to investigate malaria dynamics, hard-tick infestations, measles epidemiology, tuberculosis prevalence, and the bioactivity of plant-based nanoparticles. He has contributed to impactful studies on queen bee rearing, silver nanoparticle synthesis, and emerging public health threats, demonstrating versatility across entomology, biotechnology, and disease prevention. His technical strengths span PCR, DNA extraction, ArcGIS mapping, nanoparticle preparation, microscopy, and bioinformatics, supported by excellent analytical, leadership, and independent research capabilities. With multiple publications, conference participations, and organizational roles in scientific events, he is committed to advancing vector control strategies, molecular parasitology, and integrated pest management, making him a strong candidate for competitive research awards and future academic excellence.

Profile: Google Scholar

Featured Publications

1. Khan, M. S., Butt, N., Khan, M. H., Shoaib, M., & Javed, M. (2021). Impact of COVID-19 on the hospitality industry: A review of current findings. Journal of Hospitality and Tourism Management, 46, 205–215.

2. Rehman, N. U., Anjum, S. I., Qureshi, N. A., Khan, M. H., Albasher, G., Kaleem, M., … (2024). The effect of larval age, and wet and dry grafting, on the rearing of queen bees using the Doolittle grafting method. Entomological Research, 54(1), e12700.

3. Siraj, N. (2025). Morphomolecular identification and spatiotemporal distribution of hard ticks infesting cattle: A livestock and public health concern in selected localities of District Swat. The Research of Medical Science Review, 3(5), 33–52.
(If M. H. Khan is a co-author, it may be added accordingly.)

4. Muhammad, M. J. U., Khan, M. H., Siraj, N., Saeed, M. A., Shah, M., … (2024). Green synthesis, characterization, optimization and anti-leishmanial investigation of silver nanoparticles from Citrus sinensis L. fruit peels. Journal of Population Therapeutics & Clinical Pharmacology, 31(10), 382–392.

5. Khan, M. S. M. H., Siraj, N., Khan, A. G., & Ali, S. (2024). Epidemiological patterns, risk factors, and preventive strategies associated with measles infection in children of Tehsil Matta, District Swat, Pakistan. Journal of Population Therapeutics & Clinical Pharmacology, 31.

Chyi-Liang Chen | Molecular epidemiology | Best Researcher Award

Published on by Global Academic Awards

Prof. Chyi-Liang Chen | Molecular epidemiology | Best Researcher Award

Prof. Chyi-Liang Chen, Linkou Chang Gung Memorial Hospital Children’s Medical Center, Taiwan

🧬 Prof. Chyi-Liang Chen is an Associate Researcher at Chang Gung Memorial Hospital and the Department of Microbiology and Immunology, Chang Gung University, Taiwan. He earned his BSc, MSc, and PhD in Life Sciences from National Chung Hsing University. With extensive postdoctoral research at Chang Gung University and the University of Calgary, his expertise spans microbiology, molecular microbiology, protein engineering, bacterial genomics, and antimicrobial resistance. He has authored numerous SCIE-indexed publications on bacterial pathogenesis and genetic engineering. His work contributes to biotechnology, genomics, and patent applications, advancing microbial research. 🦠🔬📚

Publication Profile

Scopus

Orcid

🎓 Educational Background

Prof. Chyi-Liang Chen pursued his academic journey in Life Sciences at National Chung Hsing University, Taiwan. He obtained his Bachelor’s degree (1984–1988) from the Department of Life Sciences (formerly the Department of Botany). He then completed his Master’s degree (1988–1990) at the Institute of Life Sciences (previously the Institute of Botany Microbiome). Further advancing his expertise, he earned a Ph.D. (1990–1995) from the same institute. His strong foundation in microbiology, molecular biology, and botany has significantly contributed to his impactful research in bacterial genomics and biotechnology. 🧬🔬📖

🏅 Professional Experience

Prof. Chyi-Liang Chen has an extensive career in microbiology and immunology. He began as a Postdoctoral Fellow at Chang Gung University, Taiwan (1997–1999) before moving to the University of Calgary, Canada (1999–2002). He later returned to Chang Gung University (2002–2006). He served as an Assistant Professor at Yuanzhi University and later as an Assistant Researcher at Chang Gung Memorial Hospital (2006–2012). Since 2012, he has been an Associate Researcher at Chang Gung Memorial Hospital and, from 2022, also at the Department of Microbiology and Immunology, Chang Gung University. 🧪🔬📚

🔬 Research Focus

Prof. Chyi-Liang Chen specializes in infectious diseases, microbiology, and immunology. His research spans viral infections 🦠, antimicrobial resistance 💊, and host-pathogen interactions 🏥. He has contributed to studies on multiple viral infections in children, cytomegalovirus colitis, and antiviral treatments. His work also explores the gut microbiota’s role in cancer therapy and cross-species microRNAs. Additionally, he has investigated COVID-19 therapeutics 😷 and SARS-CoV-2 variants 🧬. His studies provide crucial insights into infectious disease management, making significant contributions to global health and microbiological research. 🌍🔍

Publication Top Notes

1️⃣ Multiple viral infections and antimicrobial use in hospitalized children with respiratory illness during pandemic and early post-pandemic era, Taiwan 🦠💊 (Heliyon, 2025) 
2️⃣ Identifying the function of novel cross-species microRNAs from the excretory-secretory products of Angiostrongylus cantonensis fifth-stage larvae 🧬🦠 (Journal of Microbiology, Immunology and Infection, 2025) 
3️⃣ Maternal Infections, Antibiotics, Steroid Use, and Diabetes Mellitus Increase Risk of Early-Onset Sepsis in Preterm Neonates 🤰🦠 (Pathogens, 2025) 
4️⃣ Adequate antiviral treatment lowers overall complications of cytomegalovirus colitis among inpatients with inflammatory bowel diseases 💊🦠 (BMC Infectious Diseases, 2024) – 2 citations
5️⃣ Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer 🦠🧪 (Biomedical Journal, 2024) – 5 citations
6️⃣ Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan 💊🦠 (Journal of Global Antimicrobial Resistance, 2024) – 1 citation
7️⃣ Complete genome sequence of Bacillus halotolerans F29-3, a fengycin-producing strain 🧬🦠 (Microbiology Resource Announcements, 2024) 
8️⃣ Cytomegalovirus Diseases of the Gastrointestinal Tract in Immunocompetent Patients: A Narrative Review 🦠📖 (Viruses, 2024) – 5 citations
9️⃣ Safety, tolerability, and efficacy of intranasally-administered detoxified LTh(αK) in mild-to-moderate COVID-19 patients 💉🦠 (Human Vaccines and Immunotherapeutics, 2024) 
🔟 Worldwide SARS-CoV-2 Omicron variant infection: Emerging sub-variants and future vaccination perspectives 🦠💉 (Journal of the Formosan Medical Association, 2024) – 1 citation

Conclusion

Prof. Chyi-Liang Chen is highly suitable for the Best Researcher Award due to his strong academic background, international research experience, expertise in microbiology and bacterial pathogenesis, and high-impact publications. His work has significantly advanced molecular microbiology and biotechnology, making him a worthy candidate for this prestigious recognition.

Pedro de Marchi | Epidemiology | Academic Engagement Excellence Award

Published on by Global Academic Awards

Dr. Pedro de Marchi | Epidemiology | Academic Engagement Excellence Award

Dr. Pedro de Marchi, ONCOCLINICAS, Brazil

Dr. Pedro de Marchi is a leading medical oncologist specializing in head and neck cancer at Oncoclínicas, Brazil. He serves as the National Leader and Medical Coordinator, alongside being a Professor of Medicine at Universidade Estadual do Rio de Janeiro. Dr. Marchi completed his MD at Universidade Federal de Santa Maria and furthered his training in internal medicine and oncology. His research focuses on the efficacy of immune checkpoint inhibitors and head and neck squamous cell carcinoma. Dr. Marchi has led several significant studies and has been involved in numerous conferences to advance cancer treatment. 🎗️👨‍⚕️📚

Publication Profile

Google Scholar

Education

Dr. Pedro de Marchi earned his MD from Universidade Federal de Santa Maria (UFSM) in 2008. He completed a residency in Internal Medicine at the Universidade Federal do Rio Grande do Sul and a Clinical Fellowship in Medical Oncology at Hospital São Lucas (PUC-RS). He further enriched his expertise through an observership at The University of Texas MD Anderson Cancer Center. Dr. Marchi holds a Master’s in Oncology from Fundação Pio XII, focusing on chemotherapy toxicity in head and neck cancer, and a PhD in Oncology, studying immune checkpoint inhibitors and biomarkers in lung cancer. 🎓💉📖

 

Experience and Service

Dr. Pedro de Marchi has an extensive career in oncology, serving as a resident at Universidade Federal do Rio Grande do Sul (2009-2011) and a Medical Oncology Fellow at Hospital São Lucas (2011-2014). He was the Head of Thoracic and Head & Neck Oncology at Barretos Cancer Hospital (2016-2020) and is currently a National Leader in Head & Neck Cancer at Oncoclínicas. In addition, he coordinates multiple fellowship programs and serves as a Professor of Medicine at Universidade Estadual do Rio de Janeiro. His leadership roles reflect his commitment to advancing oncology care and research. 🩺🌟📚

 

Honors and Awards

Dr. Pedro de Marchi was recognized with the AMRIGS Medical Qualification by the Medical Association of Rio Grande do Sul in Porto Alegre, Brazil, in 2008. This prestigious honor highlights his dedication to the medical field and his commitment to achieving excellence in healthcare. The award underscores his professional qualifications and serves as a testament to his skills as a medical practitioner. Dr. de Marchi’s achievements reflect his continuous pursuit of knowledge and his contribution to advancing medical practice in Brazil. 🏆🎓🌟

 

Research Contributions

Dr. Pedro de Marchi has made significant contributions to cancer research through various grants and contracts. As the Principal Investigator, he led studies on head and neck squamous cell carcinoma epidemiology and COVID-19 mortality determinants among cancer patients, securing substantial funding from notable organizations like MSD, AMGEN, and AstraZeneca. His research includes pivotal Phase III trials assessing innovative treatments for squamous cell carcinoma. These efforts not only advance medical knowledge but also aim to improve patient outcomes in Brazil. Dr. de Marchi’s work is essential in addressing critical health challenges in oncology. 📊🔬🎗️

 

Teaching

Dr. Pedro de Marchi plays a vital role in medical education and mentorship. He serves as a Clinical Research Mentor in the Oncoclinicas Mentorship Programme since 2024, fostering the next generation of oncologists. As a Professor at Universidade Estadual do Rio de Janeiro (UERJ), he instructs rotating medical students, enhancing their clinical skills. Additionally, Dr. de Marchi supervises postdoctoral research fellows in Internal Medicine and Thoracic and Head & Neck Medical Oncology, guiding them in their academic and clinical pursuits. His commitment to education ensures that future physicians are well-equipped for the challenges of oncology. 📚👨‍⚕️🎓

 

Conclusion

Dr. Pedro de Marchi exemplifies the qualities sought after for the Research for Academic Engagement Excellence Award. His leadership in cancer research, dedication to education, and significant contributions to the field make him a suitable candidate for this prestigious recognition.

Publication Top Notes

  • Pembrolizumab versus chemotherapy for untreated PD-L1-expressing NSCLC (KEYNOTE-042) 🌟 — Cited by: 3065, Year: 2019
  • Durvalumab plus platinum–etoposide for extensive-stage SCLC (CASPIAN) 🎯 — Cited by: 1679, Year: 2019
  • First-line nivolumab plus ipilimumab and chemotherapy in NSCLC (CheckMate 9LA) 🚀 — Cited by: 1086, Year: 2021
  • Durvalumab with/without tremelimumab for extensive-stage SCLC (CASPIAN) ⚖️ — Cited by: 487, Year: 2021
  • CheckMate 9LA 2-year update: nivolumab plus ipilimumab and chemotherapy vs. chemotherapy alone 🕒 — Cited by: 172, Year: 2021
  • Lung cancer in Brazil 🇧🇷 — Cited by: 142, Year: 2018
  • PD-L1 expression in NSCLC: TPS vs. CPS 🧬 — Cited by: 77, Year: 2021
  • Câncer de pulmão no Brasil 📈 — Cited by: 70, Year: 2018
  • MiR-21 as a prognostic biomarker in head and neck SCC 📊 — Cited by: 69, Year: 2017
  • Determinants of COVID-19 mortality in cancer patients in Brazil 🦠 — Cited by: 50, Year: 2021